We previously performed gene expression profiling in a multistep squamous cell carcinoma (SCC) progression model, and identified growth-regulated oncogene-1 (Gro-1/KC) as a factor that contributes to enhanced angiogenesis, tumorigenesis and metastasis. In the present study, we explored molecular pathways coactivated with Gro-1/ KC, and identified a transcript that encodes c-Met, the receptor for hepatocyte growth factor/scatter factor (HGF). Northern, Western blot, and immunohistochemical analyses confirm that expression of c-Met mRNA and protein is increased with SCC progression. In vitro, HGF preferentially promoted scattering in the metastatic LY-1 and LY-2 lines, and enhanced angiogenesis factors Gro-1/ KC and vascular endothelial growth factor (VEGF) production by all tumor cell lines. In vivo, tumor growth and lung metastasis were promoted by transfection and overexpression of HGF cDNA in metastatic LY-1 cells. Our data indicate that metastatic SCC cells that overexpress c-Met exhibit angiogenesis factor expression and enhanced scattering in response to HGF in vitro, and tumorigenesis and metastasis in response to HGF in the tumor microenvironment in vivo.
Introduction
Squamous cell carcinomas (SCC) comprise a significant portion of the cancers that arise from the epithelium of the upper aerodigestive tract and skin. Malignant progression of SCC is manifested by increased potential for cell proliferation and survival, deregulated cell differentiation, inflammatory and angiogenic cytokine production, and invasion and metastasis (Yuspa et al., 1994; Chen et al., 1997; Smith et al., 1998) . The events mediating cancer progression and metastasis include genetic changes affecting key signaling pathways that regulate cell growth, survival, and motility, as well as expression of inflammatory and angiogenesis factors and other genes that promote pathogenic interactions between tumor cells and the host environment (Hanahan and Weinberg, 2000; Liotta and Kohn, 2001 ). The coactivation of signaling pathways and gene programs commonly results from overexpression or mutations of signal receptors and kinases that promote responsiveness to factors produced in the tumor microenvironment by malignant or stromal cells.
To identify key pathways and coordinately activated genes expressed with progression and metastasis of SCC, we previously performed global gene expression profiling in a multistep murine SCC model (Dong et al., 2001a) . This model includes primary keratinocytes, the transformed SCC cell line Pam 212, and the rare metastases of Pam 212 derived from lymph nodes (LY) and lungs (LU) in syngeneic BALB/c mice (Yuspa et al., 1980; Chen et al., 1997) . The phenotypic and genetic changes observed in this model have thus far been found to be highly relevant to human SCC. For example, the stepwise changes in patterns of growth and metastasis in this model have been linked to expression of angiogenesis factors, such as the C-X-C chemokine Gro-1/KC, and expression of other genes related to activation of the Nuclear Factor kappaB (NF-kB) signal pathway Loukinova et al., 2000) . Identification of these factors has facilitated demonstration of the clinical and functional importance of expression of several angiogenesis factors and constitutive activation of NF-kB in human head and neck squamous cell carcinoma (HNSCC) Duffey et al., 1999) .
As a result of these molecular profiling studies, we identified another candidate from a pool of cDNA fragments overexpressed along with Gro-1/KC and the metastatic phenotype. We confirmed that candidate cDNA is derived from the 3 0 untranslated region of the gene encoding c-Met, a member of the receptor tyrosine kinase family. c-Met, together with its ligand, hepatocyte growth factor/scatter factor (HGF/SF, HGF hereafter), contributes to cell survival, migration, and endothelial proliferation (Vande Woude et al., 1997; Birchmeier et al., 2003) . In serum of patients with HNSCC, we detected elevated levels of HGF together with a human C-X-C chemokine homologue, IL-8, and vascular endothelial growth factor (VEGF), suggesting that HGF/c-Met signaling might contribute to coexpression of C-X-C and other key angiogenesis factors by tumor cells (Dong et al., 2001b) . We confirmed that HGF promotes expression of angiogenesis factors IL-8 and VEGF by HNSCC in vitro (Dong et al., 2001b) . Several reports provide evidence that overexpression of HGF and c-Met also correlates with metastasis and poor survival in patients with HNSCC (Marshall and Kornberg, 1998; Cortesina et al., 2000; Aebersold et al., 2001; Qian et al., 2002) . Together, these observations suggest that HGF/c-met signaling is important in progression and metastasis of SCC.
To determine the contribution of HGF/c-Met pathway and coactivated genes to progression and metastasis of SCC, we examined the role of HGF/c-Met pathway on expression of angiogenesis factors and on promotion of tumorigenesis and metastasis in our syngeneic murine SCC model, where homology between tumor and host ligands and receptors can be assured. Herein, we show that c-Met is overexpressed in SCC lymph node and lung metastatic reisolates compared with parental or unrelated transformed keratinocytes. HGF was able to induce the production of both Gro-1/KC and VEGF in transformed and metastatic SCC, and preferentially promoted scattering in the metastatic lines. When engineered to overexpress HGF in the tumor microenvironment, metastatic SCC cells exhibited increased tumorigenic and metastatic potential in vivo. The contribution of HGF/c-Met activation to coexpression of angiogenesis factors, tumorigenesis, and metastasis make it an important therapeutic target for SCC.
Results

Upregulation of c-Met transcripts identified by mRNA differential display (DD) in the highly metastatic SCC lines
To identify transcripts that were overexpressed with SCC tumor progression in vivo, we carried out mRNA differential display and compared mRNA expression profiles in a murine SCC progression model, including primary BALB/c keratinocytes; the Pam 212 tumorigenic line with low metastatic potential, three lymph node metastatic lines (LY-1, -2, -8) and one lung metastatic line (LU-1) derived from Pam 212 parental cells. . A 310-bp candidate cDNA was found in LY-1, LY-2, and LU-1, but not in keratinocyte, Pam 212, and LY-8 lines in the panel of cDNA amplified by primers HT 11 -C and H-AP41 (Figure 1a ). We verified that the candidate cDNA fragment by Northern blot analyses (Figure 1b) , and detected a major specie of 6-7 kilobase (kb), strongly expressed by LY-1, -2, and LU-1 cell lines. We examined the mRNA expression in mouse tissues by Northern blot analysis and found that the candidate gene was strongly expressed in lung, liver, muscle and kidney, weakly in heart and brain, and at undetectable levels in spleen and testis, suggestive of preferential expression in epithelial-rich tissues (Figure 1c) . A 2.2 kb cDNA sequence was obtained through cDNA cloning using the identified DD fragment as the probe. By homology analysis in an annotated mouse genome database available through the Celera Discovery System, we verified that the cloned sequence was derived from murine c-Met 3 0 untranslated region (see Materials and methods for details). Since c-Met mutation has been reported in human solid tumors, especially in papillary renal carcinoma (Schmidt et al., 1997; Zhuang et al., 1998) (Chan et al., 1988; Iyer et al., 1990) . By comparison, c-Met was only weakly detected in four isolates of murine neonatal primary keratinocytes (lane 1-4), a carcinogen-transformed nontumorigenic mucosal keratinocyte cell line (lane 5), and a panel of chemical carcinogen-induced murine oral mucosa SCC lines that are relatively weakly tumorigenic and lack metastatic potential (lanes 6-9) . As a loading control, the blots were reprobed with the antibody 
HGF induces angiogenic cytokines Gro-1/KC and VEGF expression by Pam 212 and LY cells
To test the hypothesis that HGF contributes to angiogenic factor production in Pam 212 and LY tumor cells, we treated cells with different doses of HGF and measured expression of angiogenic cytokines Gro-1/KC and VEGF 24 h after treatment (Figure 4 ). Unstimulated Pam 212 cells produced relatively lower level of constitutive Gro-1/KC when compared with LY cells, (a,b). After stimulation by HGF, a dose-dependent increase of both Gro-1/KC (a,c,e) and VEGF production (b,d,f) were observed. In LY-2 cells, HGF induced a 40% increase of Gro-1/KC production, and the induction reached a plateau at 50 U/ml (c). When the cytokine production was calculated on a per cell basis, the induction of both cytokines by HGF was the highest in These experiments were repeated in serum-free conditions to rule out interference from serum factors, and similar results were observed (data not shown). We conclude that the HGF/c-Met pathway is one of the important inducers of Gro-1/KC and VEGF angiogenesis factor production by SCC cells. (Figure 6g,h) . We studied the effects of HGF on Pam 212 and LY cell growth by cell counts with trypan blue exclusion (Figure 7) . No significant stimulation of cell growth was observed for 72 h, and HGF significantly suppressed LY-1 cell growth at day 3 ( Figure 7 ). HGF suppression of LY-1 cell growth did not seem to be due to the induction of cell death. Using trypan blue exclusion, we did not find a significant cell death after treatment with HGF (data not shown). We also repeated the experiment with the higher dose of HGF (40 ng/ml), and the same result was observed (data not shown).
Enforced expression of HGF promotes SCC growth and metastasis in vivo
To directly examine if HGF produced in the tumor microenvironment contributes to tumorigenesis and/or metastasis, we enforced expression of HGF in SCC by transfecting Pam 212 and LY cell lines with the expression vector containing full-length cDNA for human HGF. After G418 selection, transfectants were obtained from all cell lines with the expression of HGF in the range of 1-3 ng/ml. The expression of human HGF was transient in most clones obtained, and sustained in two clones from LY-1, which we designated as HGF-2 (HGF high producer) and HGF-14 (HGF low producer). We inoculated HGF-2 and -14 cells, empty-vector transfected cells (LY-1 PMB1) , and the LY-1 cells (parental) subcutaneously into BALB/c mice. Tumor growth was measured, and the tumor bearing mice were killed at day 35 after tumor inoculation, and the presence of spontaneously metastatic lung nodules was quantified. HGF-2 showed significantly faster tumor growth (Figure 8a ) and higher number of lung metastasis (Figure 8b ) compared with the parental cells, the empty vector transfected cells, and HGF-14 (HGF low producer). The morphology of the lung metastatic nodules was the same as presented previously . These results provide direct evidence that HGF/c-Met pathway contributes to aggressive growth and metastasis of SCC in vivo.
Discussion
HGF has been previously reported to have direct effects in promoting growth and motility of SCC and endothelia (Bussolino et al., 1992; Grant et al., 1993) . Our studies provide evidence for another novel potential mechanism of promoting malignant progression of SCC involving HGF/c-Met, specifically, enhancing the expression of known angiogenesis factors Gro-1/KC and VEGF (Figures 4 and 5) . Gro-1/KC is a murine homologue of human GRO-1 and IL-8 in the C-X-C chemokine family that serve as chemoattractants for neutrophils and endothelial cells. Our laboratory and others have investigated the activity of this family of chemokines, and shown the importance of murine Gro-1/KC and human GRO-1/IL-8 in promoting angiogenesis, tumorigenesis and metastasis (Luan et al., 1997; Chen et al., 1998 Chen et al., , 1999 Smith et al., 1998; Kitadai et al., 1999; Loukinova et al., 2000; Crowl-Bancroft et al., 2001 ). In the current study, we also show that HGF/cMet promoted expression of VEGF, a potent mitogen and survival factor for endothelial cells, and one of the most prominent angiogenic factors produced by many types of tumor cells including SCC (Ferrara, 2002) . Although HGF induced VEGF production has been reported in several human cancers, including HNSCC by our laboratory (Wojta et al., 1999; Dong et al., 2001b; Zhang et al., 2003) , HGF induced VEGF production in murine tumors has not been previously studied. Constitutive and HGF induced Gro-1/KC and VEGF with c-Met expression suggest they are important in promoting angiogenesis, tumorigenesis and metastasis in SCC. Based on these observations, we recently completed studies of cytokine expression using serum and cell lines from patients with HNSCC that provide corroborating evidence for a role of HGF in expression of the human angiogenesis factors IL-8 and VEGF by SCC. We detected increased HGF with IL-8 and VEGF in the serum of patients with HNSCC, suggesting a possible linkage between expression of HGF and these other angiogenesis factors (Dong et al., 2001b) . HGF was found to induce IL-8 and VEGF mRNA and protein expression in a panel of eight cell lines from patients with aggressive HNSCC, but not in normal human keratinocytes, indicating that the c-Met pathway is also differentially responsive to HGF in aggressive human HNSCC. Recently, we have confirmed that human GRO-1 is also significantly increased along with HGF in serum of patients with HNSCC (C Harkins, unpublished data). Upregulated IL-8, GRO-1 and VEGF gene expression has also HGF/c-Met-mediated angiogenesis in carcinoma G Dong et al been identified in HNSCC and several other types of cancers by independent groups using microarray (Leethanakul et al., 2000; Sorlie et al., 2001) , providing further evidence for the importance of these angiogenic factors in SCC. Enforced expression of HGF promoted LY-1 tumor growth and lung metastasis in vivo (Figure 8) . HGF was able to induce scattering in LY-1 cells (Figure 6 ), consistent with its role in promoting metastasis in vivo. In vitro, HGF did not have a significant effect on the proliferative rate of Pam 212 and LY-2 cell growth (Figure 7) . HGF-treated LY-1 cells grew relatively slower after treatment with HGF for 3 days (Figure 7) , and HGF-transfected clones grew relatively slower than the vector-transfected clone (data not shown). Thus, it is likely that the accelerated in vivo growth of HGFtransfected LY-1 tumors was due to the indirect host-related effects, such as angiogenesis. A similar phenomenon has been observed in Gro-1/KC-transfected Pam 212 cells, where Gro-1/KC, overexpression did not promote increased cell growth in vitro, but accelerated tumor growth, angiogenesis, and lung metastasis (Loukinova et al., 2000) . Since HGF significantly induced Gro-1/KC and VEGF production by LY-1 cells (Figure 5 ), it is likely that the accelerated tumor growth and increased lung metastasis in vivo were due to the combinational effects of HGF, Gro-1/KC, and VEGF. It has been shown previously that other tumor cells transfected with HGF grow more aggressively than their parental cells expressing c-Met receptor alone (Rong et al., 1993; Takayama et al., 1997) . The neutralizing antibody against c-Met receptor is able to block primary tumor growth and metastasis (Cao et al., 2001) . Yu et al. recently showed that a nonautocrine interaction between HGF transgenic hosts and c-Met expressing melanoma cells significantly promotes tumor metastasis in vivo (Yu and Merlino, 2002) . Clinically, elevated serum HGF levels have been found in patients with cancers from bladder, breast, colon, gastric, liver, lung and head and neck (Takigawa et al., 1997; Taniguchi et al., 1997; Fukuura et al., 1998; Toi et al., 1998; Junbo et al., 1999; Gohji et al., 2000; Naughton et al., 2001; Uchida et al., 2001 , Dong, 2001b . Significantly, this elevated serum HGF is associated with poor prognosis.
Evidence for the broad importance of c-Met overexpression has been obtained in different cancer types, including human HNSCC, esophageal, hepatocellular and breast cancers, as well as in rat mammary carcinoma (Hu et al., 2001; Sorlie et al., 2001; Takeo et al., 2001) . In HNSCC, overexpression of c-Met has been demonstrated as an important pathological marker for tumor metastasis (Marshall and Kornberg, 1998; Porte et al., 1998; Cortesina et al., 2000; Aebersold et al., 2001; Qian et al., 2002) . In these studies, c-Met protein expression was significantly correlated with lymph node status and poor prognosis. In a recent clinical study involving 97 oropharyngeal cancer patients, immunostaining of HGF, c-Met and Bcl-xL were identified as the strong indicators for radiation resistance and poor overall survival of the patients (Aebersold et al., 2001) . Qian et al. showed that the c-Met protein expression level is correlated with decreased survival in the patients with late-stage nasopharyngeal carcinomas (Qian et al., 2002) . In this study, we show that LY-1 and LY-2 tumor cells selected by the host in the metastatic stage exhibit increased expression and activation of c-Met (Figures 1  and 2 ). Such overexpression and activation is associated with their scattering effects in vitro, and accelerated tumor growth and lung metastasis in vivo, in responding to HGF (Figure 8) . Upregulation of c-Met is one of the important molecular mechanisms that contribute to tumor progression and metastasis in this model, which has demonstrated other important molecular changes shown to be relevant to human SCC Loukinova et al., 2000) .
In summary, we have provided evidence that liganddependent c-Met activation contributes to tumor progression and metastasis in this murine SCC model. c-Met was overexpressed by most metastatic variants (Figures 1 and 2) , and HGF and c-Met were detected in the tumor environment in vivo by immunohistochemistry (Figure 3 ). Constitutive activation of c-Met in LY-2 cells could be completely blocked by anti-c-Met neutralizing antibody in vitro (Figure 2b) . Metastatic LY cells exhibited higher proangiogenic cytokines, Gro-1/KC and VEGF, and HGF could further induced the production (Figures 4 and 5) . HGF only induced scattering effects in the metastatice LY lines (Figure 6 ). When LY-1 cells were transfected with the human HGF gene, these tumors grew more aggressively and formed more lung metastasis than controls (Figure 8 ). All these data suggest that HGF-induced c-Met activation is an important mechanism promoting tumorigenesis and metastasis of murine SCC. Such an animal model provides a unique system to further investigate HGF/ c-Met-mediated tumor progression and metastasis, as well as to test pharmacological reagents targeting HGF/ c-Met pathways.
Materials and methods
Reagents and cell lines
Human recombinant HGF was either kindly provided by Dr Vande Woude at NCI or purchased from R&D Systems (Minneapolis, MN, USA). Antibody to HGF (Cat. sc-7949), cMet , phospho-tyrosine (Cat. PY99), and Protein G PLUS Agarose were from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA). Goat anti-cMet neutralizing antibody was from R&D systems (Cat. AF527). Rabbit polyclonal anti-mouse cytokeratin 6 was from Covance Research Products, Inc, (Richmond, CA, USA). Madin-darby canine kidney epithelial cells (MDCKII) were kindly provided by Dr Vande Woude.
The primary keratinocytes, Pam 212 and derived metastatic lines isolated from the lymph node (LY) and the lung (LU) metastases were described previously (Yuspa et al., 1980; Chen et al., 1997) . B4B8-Scid, B7E3-Scid, B6C3-Scid, and B6D8-Scid are carcinoma lines induced by chemical carcinogen 4NQO from BALB/c oral mucosa . B7E11-keratinocyte is a 4NQO transformed keratinocyte line that is nontumorigenic in vivo (G Thomas and Z Chen, unpublished data) . All tumor lines were grown in EMEM plus 10% fetal bovine serum (FBS) and penicillin, streptomycin, and glutamine.
RNA isolation, mRNA differential display, and Northern blotting Total RNA was isolated from cells using Trizol reagent (Life Technologies Inc, Gaithersburg, MD, USA). mRNA differential display (DD) was performed with RNAimage kits (GenHunter Co., Brookline, MA, USA) following the manufacturer's instructions (Dong et al., 2001a) . Northern blotting analyses were performed using 20 mg of total RNA or 1.5 mg polyA þ RNA as described previously (Dong et al., 2001a) . Multi-tissue blots for Northern blot analysis were purchased from Clontech (Palo Alto, CA, USA).
cDNA cloning and bioinformatic confirmation of murine c-Met
A lambda Zap II mouse lung cDNA library, established from the 6 to 8 week female mice of (C57BL/6XCBA) F1J mice, was purchased from Stratagene (Cat. 936387, La Jolla, CA, USA). Following the final round screening, seven cDNA clones were obtained from 1 Â 10 6 phage plaques with the inserts of 250-2280 bp long. The consensus sequences were used to search in Genbank and mouse genome and transcript database from Celera Discovery System (Applied Biosystems, Foster City, CA, USA). The sequence from nucleotide (nt) 7-193 was identical to the 3 0 187 bases of mouse c-Met published previously which include 3 0 127-base coding sequence and a 60-base 3 0 untranslational region for c-Met (Accession: NM_008591).
To further confirm that the identified cDNA sequences are part of the transcripts derived from c-Met gene, we searched cDNA sequences against the annotated mouse genome database available through the Celera Discovery System. Our cDNA sequences were mapped to a single locus in murine chromosome 6, from nt #14 647 173 to #14 649 398. The entire 2280 bp sequence was aligned with the last 127 bp sequences of c-Met predicted exon 20 and all downstream exons (data not shown). ELISA, scattering assay, and cell count
To quantify cytokine Gro-1/KC and VEGF levels using commercially available 96-well plate ELISA (R and D systems, Minneapolis, MN, USA), supernatants were collected from the 24-well plate with 5 Â 10 4 cells plated the day before and treated with various doses of recombinant HGF. The optical density of the colorimetric reaction was measured by a microplate autoreader at 450 nm. The concentration of cytokines was extrapolated from a standard curve performed by using recombinant cytokines. Data were presented as the mean of duplication, and the experiments were repeated three times. To measure the cytokine production level on the per cell basis, cells were plated in the six-well plate at 1 Â 10 5 cells per well, and treated with HGF the next day. Then the culture supernatant were collected 72 h after HGF treatment. The cells were harvested by trypsinization, stained with trypan blue and counted by hemocytometer under the light microscope.
For the scattering assay, SCC cells were plated at 1X10 4 cells per well in the 24-well plates and incubated overnight. Next day, cells were washed twice with serum-free medium and incubated with recombinant HGF at different doses. Cell scattering was examined 24-48 h after the addition of HGF and photographed at Â 100 magnification.
Cell extracts, Western blot analyses, and Immunoprecipitation
Whole cell extracts were made as described previously . Protein concentrations were determined using a BCA protein assay kit following the manufacturer's instructions (Pierce, Rockford, IL, USA). For Western blot analysis, 50 mg of cell extracts were loaded on an 11 Â 14 cm denaturing SDS-PAGE, transferred onto the nitrocellulose membranes and incubated with polyclonal rabbit antibody to c-Met (Santa Cruz, Cat. sc-371, Santa Cruz, CA, USA) followed with goat anti-rabbit IgG-HRP conjugate (Cat. 170-6515, Bio-Rad, Hercules, CA, USA). Membranes were developed in chemiluminescent substrate (Cat. 34080, Pierce, Rockford, IL, USA) and exposed to films.
Met receptor phosphorylation was examined by immunoprecipitation with an anti-c-Met antibody followed by Western blotting using antiphosphotyrosine antibody. Total protein was extracted using nuclear extract kit (Active Motif, Carlsbad, CA, USA). Total protein 500 mg of was immunoprecipitated with mouse antibody against c-Met (Santa Cruz, CA, USA) according to Santa Cruz protocol. The immunoprecipitated samples were resuspended in 5 ml 4X Laemmli loading dye (containing b-mercaptoethanol), and Western blot analysis was performed as described.
Immunohistochemistry
Immunohistochemical staining of HGF and c-Met in murine SCC tumors was performed according to the manufacturer's suggestion (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA). Frozen sections (10 mm) were prepared from tumor specimens of Pam 212 and LY tumors. The frozen sections were fixed and permeabiolized in freshly made cold methanol/ acetone at 1 : 1 for 5 min at 41C. The primary antibodies: 4 mg/ ml of rabbit anti-HGF, 4 mg/ml of rabbit anti-c-Met, 2 mg/ml of rabbit anti-murine cytokeratin K6, or, rabbit IgG were incubated at room temperature for 2 h. An ABC method (Vectastain Elite ABC kit) with chromogen DAB (Diaminobenzidine tetrahydro-chloride) was then performed according to the manufacturer's instructions (Vector Lab, Burlingame, CA, USA). The slides were counterstained with hematoxyilin (Fisher Scientific, Pittsburgh, PA, USA).
Stable transfection of SCC with human HGF expression vectors
Pam 212 and LY cells were transfected with an expression plasmid for human HGF by inserting the 2.3 kb BamHI-KpnI fragment of the human HGF sequence into the BamHI-KpnI site of pMEX (Rong et al., 1992) . Transfection was carried out by using Lipofectamine (Life Technology, Gaithersburg, MD, USA) following the manufacturer's recommendations. The transfected cells were selected in G418-containing medium for 2 weeks and cloned by screening for HGF production by ELISA.
Growth and metastasis of tumors in normal syngeneic BALB/c hosts
Pam 212, LY-1, and LY-1 cells transfected with empty vector or HGF vector were harvested from culture during logarithmic growth phase, and injected subcutaneously into normal syngeneic BALB/c mice at a dose of 5 Â 10 6 cells per mouse. Tumor size was measured weekly with an engineering caliper and presented as tumor area (tumor width Â tumor length). After tumor area reached approximately 2 cm 2 , the mice were euthanized by CO 2 inhalation. The lungs were removed and stained in Bouin's solution for 5 days (Sigma Co, St Louis, MD, USA), and lungs with visible metastatic colonies were counted. * indicates the statistical significance by t-tests (Po0.05)
